Hey there,
In cancer research, there's a brutal truth, even the most advanced treatments can stop working without warning.
For years, scientists have known why: tumors use a "Don't Eat Me" signal to hide from the immune system.
Billions have been spent trying to block it. Some succeeded but only for a while. The problem?
Earlier drugs attacked healthy blood cells, causing dangerous side effects.
Now a small U.S. biotech believes it's cracked the code. Their next-generation therapy targets tumors and immune cells — while sparing healthy ones.
In preclinical testing, it triggered aggressive immune attacks on cancer without the blood safety issues that derailed its predecessors.
And they're not stopping there.
They've announced an audacious plan to launch a $500 million digital asset investment arm designed to fund their pipeline without heavy share dilution.
A move that could attract both biotech investors and an entirely new class of capital.
With human trials planned and a float so small it can move fast on headlines, this setup has all the hallmarks of a biotech story that can change quickly.
See why some investors are circling now before the next update hits the tape.
Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.
This message is a PAID ADVERTISEMENT for Liminatus Pharma Inc (NASDAQ:LIMN) from Market Jar Media Inc. StockEarnings, Inc. has received a fixed fee of $25000 from Market Jar Media Inc for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between August 14, 2025 and August 21, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Liminatus Pharma Inc (NASDAQ:LIMN) or Market Jar Media Inc. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Liminatus Pharma Inc (NASDAQ:LIMN) on TradingWhisperer website for additional information about the relationship between Market Jar Media Inc and Liminatus Pharma Inc (NASDAQ:LIMN).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.
StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com
